<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905931</url>
  </required_header>
  <id_info>
    <org_study_id>LASH 3</org_study_id>
    <nct_id>NCT00905931</nct_id>
  </id_info>
  <brief_title>Lycopene Following Aneurysmal Subarachnoid Haemorrhage</brief_title>
  <acronym>LASH</acronym>
  <official_title>Acute Oral Lycopene Therapy on Cerebral Autoregulation and Delayed Ischaemic Deficits Following Aneurysmal Subarachnoid Haemorrhage (LASH): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge Theranostics Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators wish to explore the potential neuroprotective effects of
      acute oral supplementation of lycopene, a natural anti-oxidant derived from tomatoes, on
      cerebral vasospasm and autoregulation, and examine whether any improvements translate into a
      reduction of biochemical markers of vascular injury and inflammation a decrease in the
      prevalence of secondary strokes following subarachnoid haemorrhage.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of vasospasm</measure>
    <time_frame>Daily for 21 days</time_frame>
    <description>Mean flow velocity in MCA &gt; 120 cm/min; LR &gt; 3 (4 if age &lt; 50 years old)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of impaired autoregulation measured with transcranial Doppler</measure>
    <time_frame>Daily for 21 days</time_frame>
    <description>Transient hyperaemic response test; Mx</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of biochemical markers of vascular injury: LDL, oxy-LDL, CRP, circulating endothelial cells, endothelial progenitor cells</measure>
    <time_frame>Days: 0, 3, 6, 12, 14, 21</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Aneurysm</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lycopene</intervention_name>
    <description>30 mg oral, daily, for 21 days</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>starch</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: &gt; 18 years old,

          -  Confirmed aneurysmal subarachnoid hemorrhage (aSAH),

          -  Time from ictus &lt; 96 hours

        Exclusion Criteria:

          -  Age: &lt; 18 years old,

          -  Non-aneurysmal SAH,

          -  Time from ictus &gt; 96 hours,

          -  Severe carotid atherosclerotic disease (â‰¥70%)

          -  High-dose statin therapy (&gt;80 mg/day fluvastatin; &gt;40 mg/day simvastatin; &gt;40 mg/day
             pravastatin; &gt;10 mg/day atorvastatin; &gt;10 mg/day rosuvastatin 28),

          -  Allergy or hypersensitivity to tomatoes and tomato products and history of any other
             significant atopy/allergy (e.g. soy, whey, lutein, lecithin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J Kirkpatrick, FRCS(SN)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Hills Road, CB2 0QQ Cambridge, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karol P Budohoski, MD</last_name>
    <phone>(0044)1223331763</phone>
    <phone_ext>72831763</phone_ext>
    <email>kpb26@cam.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter J Kirkpatrick, FRCS(SN)</last_name>
      <phone>(0044)1223245151</phone>
      <email>pjk21@medschl.cam.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Karol P Budohoski, MD</last_name>
      <phone>(0044)1223 331763</phone>
      <email>kpb26@cam.ac.uk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Verghese M, Sunkara R, Shackelford L, Walker LT. Lycopene and cardiovascular diseases. In Preedy VR, Watson RR Ed. Lycopene: nutritional, medicinal and therapeutic properties. Science Publishers, New Hampshire, USA 2008.</citation>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr Peter John Kirkpatrick</name_title>
    <organization>Addenbrooke's Hospital</organization>
  </responsible_party>
  <keyword>Aneurysmal subarachnoid hemorrhage (aSAH)</keyword>
  <keyword>Cerebral vasospasm</keyword>
  <keyword>impaired cerebral autoregulation</keyword>
  <keyword>transient hyperaemic response test</keyword>
  <keyword>delayed ischaemic neurological deficits</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lycopene</mesh_term>
    <mesh_term>Carotenoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

